Oncolytic viruses: a new class of immunotherapy drugs

Nature Reviews. Drug Discovery
Howard L KaufmanAndrew Zloza

Abstract

Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity. The molecular and cellular mechanisms of action are not fully elucidated but are likely to depend on viral replication within transformed cells, induction of primary cell death, interaction with tumour cell antiviral elements and initiation of innate and adaptive anti-tumour immunity. A variety of native and genetically modified viruses have been developed as oncolytic agents, and the approval of the first oncolytic virus by the US Food and Drug Administration (FDA) is anticipated in the near future. This Review provides a comprehensive overview of the basic biology supporting oncolytic viruses as cancer therapeutic agents, describes oncolytic viruses in advanced clinical trials and discusses the unique challenges in the development of oncolytic viruses as a new class of drugs for the treatment of cancer.

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·L RaoE White
Dec 1, 1985·The Journal of Experimental Medicine·H G Ljunggren, K Kärre
Jan 16, 1971·Lancet·G Pasquinucci
May 16, 1981·Lancet·A M TaqiA F Fleming
Oct 1, 1993·European Journal of Immunology·C ErtelP von Hoegen
Mar 14, 1998·Journal of Virology·R TomazinD C Johnson
May 26, 1999·Human Gene Therapy·J R HermanP T Scardino
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·M GromeierE Wimmer
Oct 6, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·M TodaS D Rabkin
Oct 24, 2000·Journal of Virology·D M Shayakhmetov, A Lieber
Feb 28, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hiroaki WakimotoE Antonio Chiocca
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew L PecoraRobert M Lorence

❮ Previous
Next ❯

Citations

Dec 2, 2015·Drugs·Sarah L Greig
Mar 5, 2016·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Apr 5, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·K TaipaleA Hemminki
May 7, 2016·BMC Medicine·Sofia FarkonaIvan M Blasutig
May 7, 2016·Chemical Society Reviews·Amy M Wen, Nicole F Steinmetz
Jun 4, 2016·Molecular Therapy. Methods & Clinical Development·Sandeep Rp KumarRoland W Herzog
Jul 9, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Luis Alfonso RojasRamon Alemany
Jul 21, 2016·Journal for Immunotherapy of Cancer·Leisha A EmensHoward L Kaufman
Jul 13, 2016·Therapeutic Delivery·Haider Sami, Manfred Ogris
May 21, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stephanie Downs-CannerDavid L Bartlett
Jul 14, 2016·EBioMedicine·Caroline J BreitbachJohn C Bell
Jul 28, 2016·Biochemical Pharmacology·Alexandra M MowdayAdam V Patterson
Aug 9, 2016·Current Opinion in Virology·Dipongkor SahaSamuel D Rabkin
Aug 9, 2016·Annual Review of Virology·Eric JanDerek Walsh
Nov 23, 2016·Cancer·Anastasie M Dunn-Pirio, Gordana Vlahovic
Feb 15, 2017·Nature Reviews. Clinical Oncology·Qing ZhouYi-Long Wu
Mar 14, 2017·Expert Opinion on Biological Therapy·Mayuri ChandranMaria G Castro
Mar 23, 2017·Pharmacology & Therapeutics·Jason Lohmueller, Olivera J Finn
Mar 8, 2017·Cancer Science·Yuki YamamotoKazunori Aoki
Jan 24, 2017·The Cancer Journal·Praveen K BommareddyHoward L Kaufman
Jun 27, 2017·The Journal of Clinical Investigation·Linde A MilesCharles M Rudin
Jul 15, 2017·Nature Communications·Sandrine GuillardRalph Minter
Jun 24, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Stewart Sell
Jan 10, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jacob P van VlotenByram W Bridle
Mar 6, 2018·The Journal of Clinical Investigation·Praveen K Bommareddy, Howard L Kaufman
Apr 20, 2018·Cancers·Shyambabu ChaurasiyaSusanne G Warner
Feb 7, 2018·Frontiers in Immunology·Zihao XuMinghua Wu
Nov 22, 2017·Journal for Immunotherapy of Cancer·Adam Ajina, John Maher
Dec 5, 2017·Current Pharmacology Reports·Jenna H Newman, Andrew Zloza
Dec 7, 2017·Oncoimmunology·Mariona CaboLorenzo Galluzzi
Sep 1, 2017·Immunological Reviews·Peter DeinesThomas C G Bosch
Aug 5, 2017·Future Oncology·Nicolas BoisgeraultJean-François Fonteneau
Jan 16, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Yu-Qing XieLi Tang
Jun 27, 2018·The New England Journal of Medicine·Dan L Longo, Lindsey R Baden
Apr 27, 2018·International Journal of Cancer. Journal International Du Cancer·Carles UrbiolaDorothee von Laer

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
GTPase
biopsy

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Progress in Experimental Tumor Research
A E MOORE
Advances in Virology
Nanhai G ChenUlrich M Lauer
Cytokine & Growth Factor Reviews
K L NormanP W Lee
Texas Reports on Biology and Medicine
A E MOORE
© 2021 Meta ULC. All rights reserved